Lōkahi Therapeutics And Glucotrack Issue Update On LT-100 Program And ai² Asset Monetization Strategy
Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated
A company working on a diabetes medicine called LT-100 shared progress updates today. They also said they want to make money from their technology platform.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.